

**The Use of Genetically Modified Plants to
Produce Human Therapeutic Proteins:
A Global Summary of Existing Potential
Benefits and Risks**

By

Lawrence D. Tobias

August 2004

Table of Contents

| Section | | | | Topic | Page |
|---------|----|----|--|---|------|
| I. | | | | EXECUTIVE SUMMARY | |
| II. | | | | INTRODUCTION | |
| III. | | | | BACKGROUND FOR PROTEIN-BASED MEDICINES: THE EVOLUTION OF PLANT BIOTECHNOLOGY | |
| IV. | | | | CURRENT SITUATION FOR PROTEIN-BASED MEDICINES | |
| | A. | | | Current Production Methodology | |
| | B. | | | Available Biotechnology Derived Products | |
| | C. | | | Products in the Research Pipeline | |
| V. | | | | UNMET NEEDS IN PROTEIN-BASED MEDICINES | |
| VI | | | | THE POTENTIAL SOLUTION: PLANT-MADE PHARMACEUTICALS | |
| | A. | | | Background of Plant Biotechnology | |
| | B. | | | The Technology for Plant-Made Pharmaceuticals | |
| | | 1. | | Process Flow Chart | |
| | | 2. | | Types of Plants and Rationale | |
| | C. | | | Current Status of Plant-Made Pharmaceuticals | |
| | | 1. | | Products and Therapeutic Classes in Field Testing and in Clinical Trials | |
| | | 2. | | Companies Involved | |
| | D. | | | Future Potential | |
| | E. | | | Constraints for PMP | |
| | | 1. | | Intellectual Property-Related Constraints | |
| | | 2. | | Technology-Related Constraints | |
| | | 3. | | Cost-Related Issues and Ultimate Cost to Patients | |
| | | 4. | | Regulatory Constraints | |
| | | 5. | | Environmental and Social Constraints | |
| | | | | | |

| | | | | | |
|-------|----|----|----|---|--|
| VII. | | | | ISSUES SURROUNDING THE NEED | |
| | A. | | | Technological Feasibility of PMP Production Technology | |
| | B. | | | The Capacity Crunch | |
| | C. | | | The Cost Issue: PMPs vs. Alternative Platforms | |
| | D. | | | The Safety Issue | |
| | | 1. | | Environmental Perspective | |
| | | | a. | Genetically Modified Food and Animal Feed Perspective | |
| | | | b. | Summary: PMPs vs. Genetically Modified Food and Animal Feed | |
| | | 2. | | Food Industry Perspective | |
| | | 3. | | Regulatory Perspective: U.S.-Based Example of Genetically Modified and Related PMP Regulation | |
| | | 4. | | Social Acceptability Perspective | |
| | | | a. | The Role of Patient Organizations | |
| | | | b. | Bioethics | |
| | E. | | | Update | |
| VIII. | | | | SUMMARY | |
| IX. | | | | ATTACHMENTS | |
| | A. | | | Tables and Figures | |
| | B. | | | Acknowledgments | |
| | C. | | | Appendixes | |
| | D. | | | References | |
| | E. | | | Glossary of Abbreviations and Terminology | |